Table 4 HF medication in the study population, divided into quartiles based on BNP
From: Prevalence and treatment of heart failure in Swedish nursing homes
BNP quartile | 1 | 2 | 3 | 4 | p value |
|---|---|---|---|---|---|
Range (ng/L) | 10-51 | 52-102 | 103-191 | 192-4200 | |
(n = 100) | (n = 101) | (n = 101) | (n = 100) | ||
ACE inhibitors/ARBs n (%) | 14 (14) | 20 (19.8) | 20 (19.8) | 28 (28) | 0.11 |
Beta-blockers n (%) | 14 (14) | 31 (30.7) | 45 (44.6) | 54 (54) | <0.001 |
a, b, c, e | |||||
Spironolactone n (%) | 9 (9) | 4 (4) | 7 (6.9) | 7 (7) | 0.56 |
Digoxin n (%) | 2 (2) | 1 (1) | 13 (12.9) | 14 (14) | <0.001 |
b, c, d, e | |||||
Furosemide/loop diuretics n (%) | 27 (27) | 39.6 (40) | 36 (35.6) | 50 (50) | 0.009 |
c | |||||
Loop diuretics with simultaneous ACE inhibitor/ARB treatment n (%) | 6 (6) | 15 (14.9) | 13 (12.9) | 20 (20) | 0.034 |
c |